PT910399E - Composicao farmaceutica estavel de bdnf (brain derived neurotrophic factor) ¬factor neurotrofico derivado do cerebro| - Google Patents
Composicao farmaceutica estavel de bdnf (brain derived neurotrophic factor) ¬factor neurotrofico derivado do cerebro|Info
- Publication number
- PT910399E PT910399E PT97922156T PT97922156T PT910399E PT 910399 E PT910399 E PT 910399E PT 97922156 T PT97922156 T PT 97922156T PT 97922156 T PT97922156 T PT 97922156T PT 910399 E PT910399 E PT 910399E
- Authority
- PT
- Portugal
- Prior art keywords
- neurotrophic factor
- bdnf
- brain
- derived
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8156070A JPH10212241A (ja) | 1996-05-27 | 1996-05-27 | Ｂｄｎｆを安定に含有する製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT910399E true PT910399E (pt) | 2002-11-29 |
Family
ID=15619654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97922156T PT910399E (pt) | 1996-05-27 | 1997-05-26 | Composicao farmaceutica estavel de bdnf (brain derived neurotrophic factor) ¬factor neurotrofico derivado do cerebro| |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6077829A (pt) |
| EP (1) | EP0910399B1 (pt) |
| JP (1) | JPH10212241A (pt) |
| AT (1) | ATE223728T1 (pt) |
| AU (1) | AU715571B2 (pt) |
| CA (1) | CA2256410C (pt) |
| DE (1) | DE69715414T2 (pt) |
| DK (1) | DK0910399T3 (pt) |
| ES (1) | ES2183170T3 (pt) |
| PT (1) | PT910399E (pt) |
| WO (1) | WO1997045135A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010785A1 (fr) * | 1996-09-13 | 1998-03-19 | Advanced Medicine Research Institute | Compositions ophtalmiques de facteurs neurotrophiques, remedes pour troubles fonctionnels du nerf optique et procede de traitement de tels troubles |
| US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| JP4130078B2 (ja) * | 1999-06-03 | 2008-08-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | カルバペネム誘導体結晶と注射製剤 |
| AUPQ084899A0 (en) * | 1999-06-08 | 1999-07-01 | University Of Melbourne, The | Neurotrophin agonists |
| BR0112417A (pt) * | 2000-07-13 | 2003-07-01 | Daiichi Seiyaku Co | Composições farmacêuticas contendo composto dds |
| US7223406B2 (en) * | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| AU2001278981A1 (en) * | 2000-07-21 | 2002-02-05 | Tom F Lue | Prevention and treatment of sexual arousal disorders |
| US7507799B2 (en) * | 2001-05-25 | 2009-03-24 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
| DE10149030A1 (de) * | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
| US20040096828A1 (en) * | 2002-01-04 | 2004-05-20 | Lu Dyung Aina M | Cytoskeleton-associated proteins |
| US20030219696A1 (en) * | 2002-05-23 | 2003-11-27 | Moreland Gerald W. | Method and apparatus for preventing backflow in dental saliva evacuators |
| EP1587545A2 (en) * | 2003-01-13 | 2005-10-26 | Mahendra S. Rao | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| CA2610771A1 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
| WO2007087113A2 (en) | 2005-12-28 | 2007-08-02 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
| WO2008019431A1 (en) * | 2006-08-14 | 2008-02-21 | Brc Operations Pty Limited | Method and compositions for simultaneously regulating memory and mood |
| IT1396607B1 (it) | 2009-11-16 | 2012-12-14 | Hmfra Hungary Ltd Liability Company | Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso. |
| FI2504353T4 (fi) * | 2009-11-23 | 2023-11-30 | Cubist Pharmaceuticals Llc | Lipopeptidikoostumukset ja vastaavat menetelmät |
| HUE040179T2 (hu) | 2012-03-15 | 2019-02-28 | Curna Inc | Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén |
| MX2021000644A (es) | 2018-07-18 | 2021-08-19 | Manzanita Pharmaceuticals Inc | Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos. |
| JP2021019532A (ja) * | 2019-07-26 | 2021-02-18 | 花王株式会社 | 血液脳関門保護剤 |
| CA3170514A1 (en) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180820A (en) * | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| AU6909091A (en) * | 1989-12-05 | 1991-06-26 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
| US5604202A (en) * | 1990-11-13 | 1997-02-18 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of NGF growth factors to treat drug-induced neuropathy |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
-
1996
- 1996-05-27 JP JP8156070A patent/JPH10212241A/ja active Pending
-
1997
- 1997-05-26 AT AT97922156T patent/ATE223728T1/de not_active IP Right Cessation
- 1997-05-26 DK DK97922156T patent/DK0910399T3/da active
- 1997-05-26 CA CA002256410A patent/CA2256410C/en not_active Expired - Fee Related
- 1997-05-26 US US09/180,884 patent/US6077829A/en not_active Expired - Fee Related
- 1997-05-26 EP EP97922156A patent/EP0910399B1/en not_active Expired - Lifetime
- 1997-05-26 DE DE69715414T patent/DE69715414T2/de not_active Expired - Lifetime
- 1997-05-26 ES ES97922156T patent/ES2183170T3/es not_active Expired - Lifetime
- 1997-05-26 AU AU27923/97A patent/AU715571B2/en not_active Ceased
- 1997-05-26 WO PCT/JP1997/001746 patent/WO1997045135A1/en active IP Right Grant
- 1997-05-26 PT PT97922156T patent/PT910399E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69715414D1 (de) | 2002-10-17 |
| US6077829A (en) | 2000-06-20 |
| DE69715414T2 (de) | 2003-05-15 |
| EP0910399B1 (en) | 2002-09-11 |
| JPH10212241A (ja) | 1998-08-11 |
| CA2256410A1 (en) | 1997-12-04 |
| ATE223728T1 (de) | 2002-09-15 |
| EP0910399A1 (en) | 1999-04-28 |
| ES2183170T3 (es) | 2003-03-16 |
| DK0910399T3 (da) | 2003-01-06 |
| AU715571B2 (en) | 2000-02-03 |
| WO1997045135A1 (en) | 1997-12-04 |
| AU2792397A (en) | 1998-01-05 |
| CA2256410C (en) | 2007-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT910399E (pt) | Composicao farmaceutica estavel de bdnf (brain derived neurotrophic factor) ¬factor neurotrofico derivado do cerebro| | |
| ES2563677T3 (es) | Composiciones de combinaciones de Neisseria | |
| NO934355L (no) | Proteinformulering omfattende veksthormon | |
| ATE410441T1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen | |
| WO2003077835A3 (en) | Sodium dodecyl sulfate compositions for inactivating prions | |
| BR9508088A (pt) | Composição de limpeza antimicrobiana processo para desinfetar superfícies não vivas e uso em um processo para a preparação de uma coposição desinfetante | |
| WO2001041800A3 (en) | Compositions and methods for stabilizing biological molecules upon lyophilization | |
| WO1998033509A3 (en) | Useful properties of human lactoferrin and variants thereof | |
| DE69401204D1 (de) | Gonadotropin enthaltende gefriergetrocknete troepfen | |
| DK1107749T3 (da) | Anvendelse af fumarsyrederivater i transplantationsmedicin | |
| EP1572961A4 (en) | ACTRIIB FUSION POLYPEPTIDES AND USES THEREOF | |
| NO993709L (no) | Stabilisert blanding omfattende fibrinogen | |
| KR950703987A (ko) | G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf) | |
| NO20031159D0 (no) | Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner | |
| ATE264340T1 (de) | Stabilisierung von gefriergetrocknetem kuchen | |
| BR9809103A (pt) | Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos | |
| DK0641216T3 (da) | Farmaceutisk præparat indeholdende IL-6 | |
| DE69737455D1 (de) | Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben | |
| KR960705580A (ko) | 단백질 C 또는 활성화 단백질 C를 안정화시키는 방법 및 안정화된 조성물(Method of stabilizing protein C or activated protein C and stabilized composition) | |
| DK1165102T3 (da) | Matrixproteinpræparater til podning i ikke-mineraliseret væv | |
| DE60022499D1 (de) | Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten | |
| PT94685A (pt) | Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem | |
| BR0208879A (pt) | Artigo | |
| EP1174439A3 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
| WO2002012336A3 (en) | TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE |